Auxilium Pharma Q1 Loss Widens Significantly - Quick Facts

(RTTNews) - Auxilium Pharmaceuticals Inc. (AUXL) posted a wider first-quarter 2014 GAAP net loss of $56.0 million, or $1.12 per share, versus a $8.2 million, or $0.17 per share loss last year. On a non-GAAP basis, net loss for was $19.4 million, or $0.39 per share for the recent quarter. On average, 11 analysts polled by Thomson Reuters expected loss per share of $0.17 for the quarter. Analysts' estimates typically exclude one-time items.

Total revenues for the three-month period were $88.5 million, 34 percent higher than $66.2 million reported a year back, due mainly to the addition of revenues from the products acquired as part of the Actient acquisition in April 2013, as well as the launch of STENDRA and XIAFLEX for PD during the first quarter of 2014 and was partially offset by a decline in Testim revenues. Analysts estimated revenues of $89.16 million for the quarter.

In addition, the company highlighted important commercial, regulatory and clinical development updates from the quarter and, as announced earlier, updated its 2014 guidance, related mainly to lower expectations for Testim revenues for the year. For 2014, the firm now expects total revenues to be in the range of $380 million - $420 million.